Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AKUS Stock Summary
In the News
Why Is Akouos (AKUS) Stock Up 85% Today?
There's notable merger news today as pharmaceutical giant Eli Lilly (NYSE: LLY ) entered into a definitive agreement to acquire Akouos (NASDAQ: AKUS ). Clearly, Eli Lilly is looking to expand further into gene therapies.
Why Akouos Stock Is on Fire Today
A buyout agreement is lighting a fire underneath the biotech's shares today.
Eli Lilly to buy genetic medicine developer Akouos for $487 million
Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.
Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per share in cash without interest, or an aggregate of $610 million.
Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why
Akouos, Inc. (AKUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why
Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Akouos to Present at Bank of America 2022 Healthcare Conference
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.
Akouos to Participate in Upcoming March Virtual Investor Conferences
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March:
Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting
BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.
Akouos to Present at Jefferies Gene Therapy/Editing Summit
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.
AKUS Financial details
AKUS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | |
Net income per share | -0.93 | -4 | -2.77 | -4.94 | |
Operating cash flow per share | -1.05 | -3.03 | -2.32 | -3.63 | |
Free cash flow per share | -1.13 | -3.57 | -2.58 | -4.15 | |
Cash per share | 3.58 | 3.9 | 17.55 | 13.24 | |
Book value per share | -1.12 | -5.1 | 17.7 | 13.31 | |
Tangible book value per share | -1.12 | -5.1 | 17.7 | 13.31 | |
Share holders equity per share | -1.12 | -5.1 | 17.7 | 13.31 | |
Interest debt per share | 0 | 0.1 | 0.75 | 1.65 | |
Market cap | 141.56M | 141.56M | 348.03M | 149.18M | |
Enterprise value | 118.54M | 130.27M | 292.24M | 56.25M | |
P/E ratio | -23.54 | -5.5 | -7.16 | -1.72 | |
Price to sales ratio | 0 | 0 | 0 | 0 | |
POCF ratio | -21.02 | -7.26 | -8.54 | -2.34 | |
PFCF ratio | -19.48 | -6.17 | -7.68 | -2.05 | |
P/B Ratio | -19.58 | -4.32 | 1.12 | 0.64 | |
PTB ratio | -19.58 | -4.32 | 1.12 | 0.64 | |
EV to sales | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -19.9 | -5.2 | -6.29 | -0.68 | |
EV to operating cash flow | -17.6 | -6.68 | -7.17 | -0.88 | |
EV to free cash flow | -16.31 | -5.68 | -6.45 | -0.77 | |
Earnings yield | -0.04 | -0.18 | -0.14 | -0.58 | |
Free cash flow yield | -0.05 | -0.16 | -0.13 | -0.49 | |
Debt to equity | 0 | -0.02 | 0.04 | 0.12 | |
Debt to assets | 0 | 0.01 | 0.04 | 0.1 | |
Net debt to EBITDA | 3.86 | 0.45 | 1.2 | 1.12 | |
Current ratio | 4.73 | 4.4 | 29.01 | 14.06 | |
Interest coverage | 0 | 0 | 0 | 0 | |
Income quality | 1.12 | 0.76 | 0.84 | 0.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.08 | 0.18 | 0.11 | 0.14 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | -9.67 | -4.94 | -2.08 | -2.41 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
Graham number | 4.86 | 21.42 | 33.21 | 38.46 | |
ROIC | 1.27 | 1.21 | -0.15 | -0.3 | |
Return on tangible assets | -0.23 | -0.57 | -0.15 | -0.31 | |
Graham Net | -1.55 | -8.22 | 16.25 | 10.67 | |
Working capital | 18.41M | 20.2M | 299.93M | 219.36M | |
Tangible asset value | -7.23M | -32.8M | 310.61M | 233.65M | |
Net current asset value | -9.67M | -51.82M | 287.9M | 191.06M | |
Invested capital | 0 | -0.02 | 0.04 | 0.12 | |
Average receivables | 0 | 0 | 0 | 0 | |
Average payables | 0 | 383K | 617K | 1.09M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 0.83 | 0.78 | -0.16 | -0.37 | |
Capex per share | -0.08 | -0.53 | -0.26 | -0.51 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.67 | -0.72 | -0.79 | -0.58 | -0.55 | |
Operating cash flow per share | -0.57 | -0.46 | -0.58 | -0.47 | -0.57 | |
Free cash flow per share | -0.63 | -0.49 | -0.66 | -0.65 | -0.64 | |
Cash per share | 7.25 | 6.74 | 6.06 | 5.38 | 4.59 | |
Book value per share | 7.44 | 6.78 | 6.05 | 5.52 | 4.9 | |
Tangible book value per share | 7.44 | 6.78 | 6.05 | 5.52 | 4.9 | |
Share holders equity per share | 7.44 | 6.78 | 6.05 | 5.52 | 4.9 | |
Interest debt per share | 0.83 | 0.84 | 0.85 | 0.91 | 0.97 | |
Market cap | 399.81M | 292.96M | 164.01M | 168.08M | 249.48M | |
Enterprise value | 313.94M | 200.03M | 138.76M | 127.24M | 209.44M | |
P/E ratio | -4.36 | -2.94 | -1.51 | -2.02 | -3.06 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -20.21 | -18.38 | -8.18 | -9.9 | -11.82 | |
PFCF ratio | -18.51 | -17.39 | -7.18 | -7.24 | -10.53 | |
P/B Ratio | 1.56 | 1.25 | 0.78 | 0.85 | 1.38 | |
PTB ratio | 1.56 | 1.25 | 0.78 | 0.85 | 1.38 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -14.44 | -8.36 | -5.38 | -6.55 | -11.45 | |
EV to operating cash flow | -15.87 | -12.55 | -6.92 | -7.5 | -9.93 | |
EV to free cash flow | -14.54 | -11.88 | -6.07 | -5.48 | -8.84 | |
Earnings yield | -0.06 | -0.09 | -0.17 | -0.12 | -0.08 | |
Free cash flow yield | -0.05 | -0.06 | -0.14 | -0.14 | -0.1 | |
Debt to equity | 0.11 | 0.12 | 0.14 | 0.17 | 0.2 | |
Debt to assets | 0.1 | 0.1 | 0.11 | 0.13 | 0.16 | |
Net debt to EBITDA | 3.95 | 3.89 | 0.98 | 2.1 | 2.19 | |
Current ratio | 19.4 | 14.06 | 11.39 | 13.36 | 17.3 | |
Interest coverage | 0 | 0 | -103.99 | 0 | -37.01 | |
Income quality | 0.86 | 0.64 | 0.74 | 0.81 | 1.06 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.09 | 0.06 | 0.14 | 0.37 | 0.12 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.56 | -0.88 | -3.03 | -4.44 | -2.54 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.55 | 10.51 | 10.36 | 8.5 | 7.8 | |
ROIC | -0.07 | -0.09 | -0.1 | -0.08 | -0.08 | |
Return on tangible assets | -0.08 | -0.09 | -0.11 | -0.09 | -0.09 | |
Graham Net | 6.05 | 5.44 | 4.7 | 4.08 | 3.38 | |
Working capital | 241.39M | 219.36M | 192.89M | 180.33M | 164.41M | |
Tangible asset value | 256.22M | 233.65M | 208.98M | 197.95M | 180.84M | |
Net current asset value | 213.27M | 191.06M | 164.48M | 148.33M | 129.82M | |
Invested capital | 0.11 | 0.12 | 0.14 | 0.17 | 0.2 | |
Average receivables | 70.22M | 0 | 0 | 0 | 0 | |
Average payables | 1.07M | 1.17M | 1.31M | 1.01M | 620.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.11 | -0.13 | -0.11 | -0.11 | |
Capex per share | -0.05 | -0.03 | -0.08 | -0.17 | -0.07 |
AKUS Frequently Asked Questions
What is Akouos, Inc. stock symbol ?
Akouos, Inc. is a US stock , located in Boston of Ma and trading under the symbol AKUS
Is Akouos, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $13. The lowest prediction is $13 and the highest is $13
What is AKUS stock prediction ?
What is Akouos, Inc. stock quote today ?
Akouos, Inc. stock price is $- today.
Is Akouos, Inc. stock public?
Yes, Akouos, Inc. is a publicly traded company.